Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) Net Income towards Common Stockholders: 2014-2024

Historic Net Income towards Common Stockholders for Viking Therapeutics (VKTX) over the last 11 years, with Dec 2024 value amounting to -$110.0 million.

  • Viking Therapeutics' Net Income towards Common Stockholders fell 262.79% to -$90.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$237.3 million, marking a year-over-year decrease of 139.32%. This contributed to the annual value of -$110.0 million for FY2024, which is 28.17% down from last year.
  • Per Viking Therapeutics' latest filing, its Net Income towards Common Stockholders stood at -$110.0 million for FY2024, which was down 28.17% from -$85.8 million recorded in FY2023.
  • In the past 5 years, Viking Therapeutics' Net Income towards Common Stockholders registered a high of -$39.4 million during FY2020, and its lowest value of -$110.0 million during FY2024.
  • Moreover, its 3-year median value for Net Income towards Common Stockholders was -$85.8 million (2023), whereas its average is -$88.2 million.
  • Data for Viking Therapeutics' Net Income towards Common Stockholders shows a maximum YoY plummeted of 53.80% (in 2020) over the last 5 years.
  • Over the past 5 years, Viking Therapeutics' Net Income towards Common Stockholders (Yearly) stood at -$39.4 million in 2020, then slumped by 39.44% to -$55.0 million in 2021, then decreased by 25.08% to -$68.8 million in 2022, then decreased by 24.78% to -$85.8 million in 2023, then declined by 28.17% to -$110.0 million in 2024.